Actionable trade ideas with defined risk and time horizons.
Curated trade ideas across equities, options, and other instruments, featuring clear directional bias, time horizon, and risk considerations. Trade ideas are designed to align market context, technical structure, and risk management principles.
10,853 total articles
Wingstop has seen its share price collapse from cycle highs, but the underlying business - an asset-light, franchise-led model with strong FCF and a massive committed unit pipeline - still points to material upside. This trade idea lays out an actionable long with entry, stop and targets across a 45-to-180 trading-day horizon, plus catalysts and ba…
Allstate has completed a dramatic operational recovery: underwriting performance has improved, catastrophe losses are down, and investment yields are benefiting from a higher-rate environment. At $267.06 the stock trades cheaply on trailing multiples, but much of the easy upside from the turnaround is already priced in. This trade idea favors a dis…
Arm is transitioning from pure-play IP licensing toward a broader role powering agentic AI workloads through CPUs and platform-level offerings. Strong fiscal Q1 results, early AGI CPU demand, and a raised server TAM justify a mid-term long. Valuation is rich, so this trade uses defined entry, stop and target levels to manage risk while capturing up…
KeyCorp (KEY) offers a compelling risk-reward now: a ~4.3% yield, a fresh $3.0 billion buyback authorization and free cash flow of $2.18B support shareholder returns, while valuation sits at P/E ~13.5 and P/B ~1.22. We outline a structured long trade for the next 180 trading days with explicit entry, target and stop-loss levels and balanced risk fr…
Federal Agricultural Mortgage Corp (AGM) is trading on a clear fundamental and technical run: trailing EPS of $18.43, a P/E near 12.8, and a $1.60 quarterly common dividend combine with momentum indicators to argue for a mid-term long. Our trade plan targets a move to $255 with a stop at $224 and a mid-term horizon of 45 trading days.
Northrop Grumman's Q2 cadence and a reported $7.6B Sentinel-related surge sharpen program visibility for Space Systems and strategic deterrence work. With solid free cash flow, healthy returns, and bullish technicals, this trade aims to capture further re-rating over the next 45 trading days while protecting against program or macro setbacks.
Equity Bancshares (EQBK) is a small regional bank trading near $51 with a clear growth-through-acquisition strategy. Recent M&A and steady loan growth support a case for resuming outperformance; valuation is reasonable on a price-to-book of ~1.28 but P/E and EV/EBITDA are elevated. This trade idea outlines a long entry at $50.94 with a $60 target a…
Pacira (PCRX) is a sub-$1.0B market-cap specialty pharma with a recognizable non-opioid franchise (EXPAREL) and complementary assets. New real-world evidence showing large per-case cost savings, paired with improving reimbursement dynamics and a modest valuation (EV/EBITDA ~10.9; market cap ≈ $1.0B), create a tactical long opportunity. Trade plan: …
Praxis (PRAX) has shifted from clinical-stage story to commercial readiness. NDA acceptance for ulixacaltamide, blockbuster-like Phase signals on elsunersen, veteran commercial hires and heavy institutional demand create a path for outsized upside. This trade idea outlines an actionable long with entry, stop and target, and a 180-trading-day horizo…
SCZ (iShares MSCI EAFE Small-Cap ETF) offers broad exposure to Europe, Asia and the Far East small-cap complex at a reasonable valuation, a 3%+ distribution yield and bullish technicals. We prefer a mid-term long trade: entry $86.80, stop $83.00, target $92.00 over 45 trading days.
Mitek Systems (MITK) reported developments around Q3 that strengthen the bull case: improving operating momentum, partnerships expanding biometric capabilities, and a valuation that still leaves room for upside. This is a swing trade idea to capture re-rating into the mid-20s if momentum continues, with strict stop loss to limit downside.
Cresud (CRESY) remains priced like a beaten-up commodity play despite structural tailwinds from Argentina’s recent reform package and an asset base that should support a meaningful NAV rerating. This trade idea lays out a long-term (180 trading days) tactical long with defined entry, stop and target, plus the catalysts and risks that matter.
Copa Holdings' near-term volatility is likely driven by a noisy Q2 print and seasonal factors. Underneath, monthly traffic shows accelerating demand (April ASMs and RPMs +16.7% YoY) and a stable high load factor near 87%. At a $5.85B market cap with a P/E around 8.5 and a 4.55% yield, Copa looks undervalued for a capacity-constrained recovery in La…
Delcath Systems (DCTH) has traded up from its 2025 lows and is showing momentum indicators and improving fundamentals that suggest near-term headwinds are receding. With a market cap under $1 billion, positive free cash flow last reported, and heavy analyst upside expectations, a disciplined long trade captures a potential re-rating if commercial t…
dLocal is a cross-border payments rails specialist focused on emerging markets. Recent operational momentum (Q1 TPV > $14B, gross profit $119M) and Russell index inclusion are compelling catalysts. The stock trades at $14.41 with a $4.25B market cap and still looks attractive if take rates stabilize and TPV growth sustains. Trade plan: enter at $14…
Patria Investments (PAX) has delivered record 2025 fundraising and a 24% jump in FEAUM to $40.8bn, while closing strategic acquisitions that are accretive to Fee Related Earnings. The stock yields ~5.5% and trades at a market cap of ~$1.88bn. We like a long trade targeting a rerating and continued FRE growth, with an explicit entry, stop and target…
The RealReal has shown durable GMV and revenue growth alongside improving free cash flow and expanding margins. With supply broadening and retail initiatives returning, the risk/reward favors a measured long swing trade into $15, using a tight stop to respect persistent profitability risks.
Copel (CPLE6) is a classic regulated-utility story that has begun to show clear price momentum. This trade idea targets a mid-term bounce driven by tariff stability, hydro visibility and a cleaner technical set-up. Entry, stop and target are provided with a defined 45-trading-day plan and balanced risk framework.
Amazon is visibly experimenting across ads, devices, logistics and AI-enabled AWS expansion. That 'throw spaghetti on the wall' approach creates episodic rallies and pullbacks. With the stock above key moving averages, healthy profitability metrics, but negative free cash flow and stretched valuation, this is a medium-risk swing setup: enter on a m…
Hershey's recent results and guidance point to margin recovery as cocoa prices retreat. The business generates strong cash flow and offers a 3%+ yield, supporting a trade that captures upside while limiting downside with a tight stop. Valuation is premium but supported by 2026 EPS growth guidance; use a mid-term horizon to allow margins and sentime…
Magnite is benefiting from structural CTV monetization and recent AI-driven yield tools while generating positive free cash flow. The stock has momentum but looks technically extended; this trade idea lays out a disciplined long with a 180-trading-day horizon, entry at $24.99, a $34 target and a $21 stop.
Core Scientific is transitioning from owned bitcoin mining toward high-density colocation for AI and compute customers. Recent quarterly trends show colocation revenue jumping to $65M in 2025 from $24M in 2024, and the company is financing expansion with a $500M facility while aiming for 1.5GW of leasable capacity. The stock trades at growth multip…
Amylyx (AMLX) is reshaping its story around avexitide, a once-daily GLP-1 receptor antagonist for post-bariatric hypoglycemia, supported by recent pipeline momentum and improving technicals. The company trades at a market cap of roughly $2.8B with negative EPS but a clear commercial runway. This trade idea lays out a long trade with entry, targets,…
Candel Therapeutics ($CADL) is a clinical-stage immunotherapy company that has moved several programs into late-stage development and is funding launch readiness for localized prostate cancer. The stock is trading around $10.60 with a market cap near $816M. Positive phase 3 signals, a recent public offering to support commercialization, and still-h…
Amgen is trading like a steady cash machine while quietly layering optionality from a weight-loss franchise and late-stage pipeline programs. At $406.92 the market underestimates upside from product launches, durable free cash flow of $10.175B, and a healthy dividend. This trade targets $470 with a clear stop at $369 over a 180 trading-day horizon.
